An intratumoral controlled release formulation of clusterin antisense oligonucleotide and paclitaxel or docetaxel for treatment of prostate tumors
The localized controlled delivery of both phosphorothioated clusterin antisense oligonucleotide (clusterin ASO) and paclitaxel or docetaxel to prostate tumors to maintain therapeutic concentrations of the agents at the target disease site was investigated in this work. The primary objectives were...
Main Author: | Springate, Christopher Michael Kevin |
---|---|
Language: | English |
Published: |
University of British Columbia
2011
|
Online Access: | http://hdl.handle.net/2429/31160 |
Similar Items
-
An intratumoral controlled release formulation of clusterin antisense oligonucleotide and paclitaxel or docetaxel for treatment of prostate tumors
by: Springate, Christopher Michael Kevin
Published: (2009) -
An intratumoral controlled release formulation of clusterin antisense oligonucleotide and paclitaxel or docetaxel for treatment of prostate tumors
by: Springate, Christopher Michael Kevin
Published: (2009) -
Cytotoxic effects of Clusterin antisense oligonucleotides and Docetaxel on two prostate cancer cell lines
by: N. Bakhtiari, et al.
Published: (2015-06-01) -
The synergy of gemcitabine with clusterin antisense oligonucleotides in the treatment of bladder cancer
by: Glackin, A. J.
Published: (2005) -
Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin
by: Tobias Zellweger, et al.
Published: (2001-01-01)